HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Local administration of interleukin-11 ameliorates intestinal radiation injury in rats.

Abstract
Intestinal radiation injury is dose limiting during abdominal and pelvic radiotherapy and critical for the outcome after accidental whole-body radiation exposure. The multifunctional cytokine, interleukin-11 (IL-11), ameliorates the intestinal radiation response, but its clinical use is hampered by severe toxicity after systemic administration. This study addressed whether protection against intestinal radiation injury can be achieved by intraluminal administration of IL-11. Male rats underwent surgical transposition of a 4-cm small bowel loop to the scrotum. For repeated intraluminal drug administration, an ileostomy, proximal to the bowel loop in the scrotum, was created. The transposed intestinal loop was exposed to 5 Gy fractions on 9 consecutive days. Recombinant human IL-11 (rhIL-11; 2 mg/kg/d) or vehicle was given through the ileostomy from 2 days before until 2 weeks after irradiation. At 2 weeks, structural, cellular, and molecular aspects of intestinal radiation injury were assessed. rhIL-11 ameliorated structural manifestations of radiation enteropathy, including radiation injury score (6.5 +/- 0.6 in the vehicle group versus 4.0 +/- 0.3 in the IL-11 group; P = 0.001), mucosal surface area loss (0.2 +/- 0.1 versus 0.5 +/- 0.03; P < 0.0001), and intestinal wall thickening (842 +/- 66 microm versus 643 +/- 54 microm; P = 0.02), reduced postradiation transforming growth factor-beta overexpression, and reduced numbers of ED2-positive cells. Postirradiation mucosal mast cell numbers were partially restored by rhIL-11. These data show that local administration of rhIL-11 ameliorates early intestinal radiation injury and support further development of rhIL-11 to reduce manifestations of intestinal radiation injury in the clinic.
AuthorsMarjan Boerma, Junru Wang, Alexander F Burnett, Alessandro D Santin, Juan J Roman, Martin Hauer-Jensen
JournalCancer research (Cancer Res) Vol. 67 Issue 19 Pg. 9501-6 (Oct 01 2007) ISSN: 0008-5472 [Print] United States
PMID17909060 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Interleukin-11
  • Recombinant Proteins
  • Transforming Growth Factor beta
Topics
  • Animals
  • Humans
  • Interleukin-11 (pharmacology)
  • Intestinal Diseases (etiology, metabolism, prevention & control)
  • Intestinal Mucosa (metabolism)
  • Intestines (drug effects, radiation effects)
  • Male
  • Mast Cells (drug effects, radiation effects)
  • Radiation Injuries, Experimental (metabolism, pathology, prevention & control)
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins (pharmacology)
  • Transforming Growth Factor beta (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: